Fenticonazole
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 447916794 | IUPAC_name = 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)phenyl]methoxy}ethyl]-1H-imidazole | image =Fenticonazole.png
| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = prescription | routes_of_administration = ovule, spray, cream
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = | CAS_number = 72479-26-6 | ATC_prefix = D01 | ATC_suffix = AC12 | ATC_supplemental = G01AF12 (WHO) | PubChem = 51755 | DrugBank_Ref = | DrugBank = | UNII_Ref = | UNII = QG05NRB077 | KEGG_Ref = | KEGG = D02582 | ChEBI_Ref = | ChEBI = 82863 | ChemSpiderID_Ref = | ChemSpiderID = 46840
| C=24 | H=20 | Cl=2 | N=2 | O=1 | S=1 | molecular_weight = 455.4 g/mol | smiles = c1ccc(cc1)Sc2ccc(cc2)COC(Cn3ccnc3)c4ccc(cc4Cl)Cl | InChI = 1/C24H20Cl2N2OS/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20/h1-14,17,24H,15-16H2 | InChIKey = ZCJYUTQZBAIHBS-UHFFFAOYAE | StdInChI_Ref = | StdInChI = 1S/C24H20Cl2N2OS/c25-19-8-11-22(23(26)14-19)24(15-28-13-12-27-17-28)29-16-18-6-9-21(10-7-18)30-20-4-2-1-3-5-20/h1-14,17,24H,15-16H2 | StdInChIKey_Ref = | StdInChIKey = ZCJYUTQZBAIHBS-UHFFFAOYSA-N
}}
WikiDoc Resources for Fenticonazole |
Articles |
---|
Most recent articles on Fenticonazole Most cited articles on Fenticonazole |
Media |
Powerpoint slides on Fenticonazole |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Fenticonazole at Clinical Trials.gov Trial results on Fenticonazole Clinical Trials on Fenticonazole at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Fenticonazole NICE Guidance on Fenticonazole
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Fenticonazole Discussion groups on Fenticonazole Patient Handouts on Fenticonazole Directions to Hospitals Treating Fenticonazole Risk calculators and risk factors for Fenticonazole
|
Healthcare Provider Resources |
Causes & Risk Factors for Fenticonazole |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fenticonazole is an azole antifungal drug, used locally as the nitrate in the treatment of vulvovaginal candidiasis. It is active against a range of organisms including dermatophyte pathogens, Malassezia furfur, and Candida albicans.
Uses and administration
A 200-mg pessary is inserted into the vagina at bedtime for 3 nights or a 600-mg pessary is inserted once only at bedtime. Fenticonazole nitrate is also applied topically as a 2% cream or solution for the treatment of fungal skin infections.
Adverse effects
Burning and itching have been reported after the application of fenticonazole nitrate.
Intravaginal preparations of fenticonazole may damage latex contraceptives and additional contraceptive measures are therefore necessary during local administration.
References
- The Merck Index, 12th Edition. 4047